Categories: Health

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Fulcrum Therapeutics, Inc.

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employee 35,000 options to purchase shares of the company’s common stock at an exercise price of $7.27 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, September 8, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

GlobeNews Wire

Recent Posts

Envalior at K 2025 with material solutions to help customers reduce Time, Risk, Costs, and CO

At K 2025, Envalior will present its latest innovations in Sustainable & High-Performance Engineering Materials,…

23 minutes ago

Using AI to Fight Overcrowded Animal Shelters – “CALL A PET” Launches on World Animal Day

BONN, Germany, Oct. 1, 2025 /PRNewswire/ -- On October 4th, World Animal Day, the German…

23 minutes ago

Contemporary Care Introduces TMS Therapy to Naples, Florida

Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today…

2 hours ago

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET…

2 hours ago

Vantage to Join Forex Expo Dubai 2025 as Elite Sponsor

PORT VILA, Vanuatu, Oct. 4, 2025 /PRNewswire/ -- Vantage Markets is proud to announce its participation…

2 hours ago

Yutong Launches EV Long-Life Tech at Busworld Europe 2025, Secures Seven Major Awards

BRUSSELS, Oct. 4, 2025 /PRNewswire/ -- Yutong Bus ("Yutong"; SHA: 600066), a leading global electric bus…

2 hours ago